| 12.8015 1.152 (9.88%) | 08-19 12:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.94  |
1-year : | 19.79 |
| Resists | First : | 14.5 |
Second : | 16.94 |
| Pivot price | 10.17 |
|||
| Supports | First : | 10.93 |
Second : | 8.72 |
| MAs | MA(5) : | 11.31 |
MA(20) : | 9.97 |
| MA(100) : | 10.22 |
MA(250) : | 0 | |
| MACD | MACD : | 0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.6  |
D(3) : | 81.3 |
| RSI | RSI(14): 70.7 |
|||
| 52-week | High : | 16.5 | Low : | 7.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EIKN ] has closed above the upper band by 19.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 14.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.72 - 11.78 | 11.78 - 11.83 |
| Low: | 10.23 - 10.29 | 10.29 - 10.34 |
| Close: | 11.55 - 11.65 | 11.65 - 11.74 |
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Thu, 13 Aug 2026
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Thu, 06 Aug 2026
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock Titan
Mon, 03 Aug 2026
32,924,231 Common Stock of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Mon, 03 Aug 2026
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Thu, 25 Jun 2026
EIKN Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 30 Mar 2026
After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 17.3 (%) |
| Held by Institutions | 69 (%) |
| Shares Short | 4,630 (K) |
| Shares Short P.Month | 4,500 (K) |
| EPS | -6.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -224 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.08 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|